FDA Panel’s Narrow Vote to Endorse Six Peptides: A High-Stakes Shift for Drug Compounding and Med Spas

Jul 28, 2026 | News

An FDA advisory committee has voted, narrowly, to add six popular peptides, including BPC-157 and TB-500, to the federal list of raw ingredients that compounding pharmacies are allowed to use. Nothing a med spa or compounding pharmacy may lawfully offer changed that...

Navigating the Updated Georgia Rules on Nurse Protocol Agreements: What Physicians and APRNs Need to Know

May 22, 2026 | News, State-Specific Regulations

If you operate a medical practice, medical spa, or wellness clinic utilizing Advanced Practice Registered Nurses (APRNs) in Georgia, a series of critical rule updates from the Georgia Composite Medical Board deserves your immediate attention. The Board has officially...

Georgia Composite Medical Board Clarifies IV Hydration Rules: What Clinics and Prescribers Need to Know

May 20, 2026 | News, State-Specific Regulations

If you operate a medical spa, IV lounge, mobile hydration clinic, or work as a registered nurse, an advanced practice registered nurse (APRN) or physician assistant (PA) in Georgia, a newly released position statement from the Georgia Composite Medical Board deserves...

FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List

May 8, 2026 | News

The U.S. Food and Drug Administration (FDA) has officially proposed to exclude three prominent GLP-1 receptor agonists—semaglutide, tirzepatide, and liraglutide—from the 503B Bulks List. This proposal follows an evaluation where the agency determined there is no...

REMINDER: Indiana’s New Medical Spa Registration Deadline is Approaching

May 7, 2026 | News, State-Specific Regulations

Indiana Governor Mike Braun officially signed Senate Bill 282 (SB 282) into law in March 2026, signaling a significant turning point in the regulation of the state’s aesthetic medicine industry. For the first time, Indiana will implement a dedicated regulatory...

Eli Lilly’s Open Letter on Tirzepatide + B12: What the Compounding Industry Needs to Understand

Mar 12, 2026 | News

Early this morning, Eli Lilly released a public open letter warning about potential patient safety risks associated with compounded tirzepatide mixed with vitamin B12. While the implications of this letter are still developing, the message is clear: the pharmaceutical...